1 results match your criteria: "Bethesda bJohns Hopkins University School of Medicine[Affiliation]"

Spectrum of immune-mediated necrotizing myopathies and their treatments.

Curr Opin Rheumatol

November 2016

aNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda bJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Purpose Of Review: This review aims to describe the spectrum of clinical, histological, and serological features in patients with immune-mediated necrotizing myopathies (IMNMs).

Recent Findings: Autoantibodies recognizing the signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) define two unique subtypes of necrotizing myositis patient with distinct clinical features. For example, the major histocompatibility class II human leukocyte antigen allele DRB111:01 is a strong immunogenetic risk factor for developing anti-HMGCR autoantibodies whereas B5001 and DQA10104 are over-represented in patients with anti-SRP autoantibodies.

View Article and Find Full Text PDF